Weronika Lebiedzińska

Mrs. Weronika Lebiedzińska

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EPEwelina Palak
Ewelina Palak
WLWeronika Lebiedzińska
Weronika Lebiedzińska
SASławomir Anisimowicz
Sławomir Anisimowicz
MSMaria Sztachelska
Maria Sztachelska
PPPiotr Pierzyński
Piotr Pierzyński
SWSławomir Wołczyński
Sławomir Wołczyński
Bisphenol A (BPA), the most common endocrine-disrupting chemical, has been associated with male reproductive dysfunctions. Recently, it has been shown that BPA may also affect miRNAs expression. Herein, we aimed to evaluate the association of BPA levels with steroid hormone concentration and circulating miRNAs levels to investigate the potential direct effect of BPA on homeostasis in the testis environment. The level of BPA in the seminal plasma of azoospermic men was significantly higher compared to the healthy control. The concentrations of estradiol (E2) and androstenedione (A) were significantly decreased in the seminal plasma of azoospermic men compared to the normospermic men. The levels of miR-let-7a, miR-let-7b, and miR-let-7c were significantly up-regulated, and the level of miR-518f was significantly down-regulated in the seminal plasma of the azoospermic men compared to the healthy control. The level of BPA correlated negatively with sperm concentration and normal semen morphology. A significant positive correlation was found between BPA levels and miR-let-7a and miR-let-7c levels, whereas BPA negatively correlated with miR-518f levels. Our results suggest that BPA may negatively affect sperm quality. Moreover, BPA correlated with the miR-let-7a, miR-let-7c, and miR-518f levels in seminal plasma, which suggests that BPA may act directly in seminal plasma, affecting the testicular environment.

20 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Joanna KamińskaJoanna Kamińska
Joanna Kamińska
Olga Koper-LenkiewiczOlga Koper-Lenkiewicz
Olga Koper-Lenkiewicz
DPDonata Ponikwicka-Tyszko
Donata Ponikwicka-Tyszko
WLWeronika Lebiedzińska
Weronika Lebiedzińska
EPEwelina Palak
Ewelina Palak
VDVioletta Dymicka-Piekarska
Violetta Dymicka-Piekarska
The literature data regarding the risk of colorectal cancer (CRC) in the context of hormone therapy (HT), including both estrogen–progestogen combinations and estrogen alone, are inconclusive. The precise relationship underlying the action of progesterone (P4) and progesterone receptors in CRC has yet to be determined. We characterized the expression profiles of both nuclear and membrane progesterone receptors and their potential cofactors in CRC tissues. Additionally, we analyzed the P4 and NENF treatment effects on the cell proliferation and invasion of DLD-1 and HT-29 colorectal cancer cells. We observed a weak expression of the nuclear P4 receptor (PGR), but an abundant expression of the P4 receptor membrane component 1 (PGRMC1) and neuron-derived neurotrophic factor (NENF) in the CRC tissues. P4 treatment stimulated the proliferation of the DLD-1 and HT-29 CRC cells. The co-treatment of P4 and NENF significantly increased the invasiveness of the DLD-1 and HT-29 cells. A functional analysis revealed that these effects were dependent on PGRMC1. AN immunocytochemical analysis demonstrated a cytoplasmic co-localization of PGRMC1 and NENF in the CRC cells. Moreover, the concentration of serum NENF was significantly higher in CRC patients, and P4 treatment significantly increased the release of NENF in the DLD-1 cells. P4 or NENF treatment also significantly increased the IL-8 release in the DLD-1 cells. Our data may provide novel insights into the action of P4 and PGRMC1/NENF in CRC progression, where NENF may act as a potential PGRMC1 co-activator in non-classical P4 signaling. Furthermore, NENF, as a secreted protein, potentially could serve as a promising circulating biomarker candidate for distinguishing between colorectal cancer patients and healthy individuals, although large-scale extensive studies are needed to establish this.

20 April 2023 in Reproductive Biology
Verified
Journal Article
Closed access
EPEwelina Palak
Ewelina Palak
WLWeronika Lebiedzińska
Weronika Lebiedzińska
OLOana Lupu
Oana Lupu
KPKamila Pulawska
Kamila Pulawska
SASlawomir Anisimowicz
Slawomir Anisimowicz
SWSławomir Wołczyński
Sławomir Wołczyński

22 July 2024 in International Journal of Cancer
Verified
Journal Article
Open access
KPKamila Pulawska‐Moon
Kamila Pulawska‐Moon
DPDonata Ponikwicka-Tyszko
Donata Ponikwicka-Tyszko
WLWeronika Lebiedzińska
Weronika Lebiedzińska
APAgata Pilaszewicz‐Puza
Agata Pilaszewicz‐Puza
PBPiotr Bernaczyk
Piotr Bernaczyk
Nafis RahmanNafis Rahman
Nafis Rahman
Zona pellucida 3 (ZP3) expression is classically found in the ZP‐layer of the oocytes, lately shown in ovarian and prostate cancer. A successful ZP3 ovarian cancer immunotherapy in transgenic mice suggested its use as an attractive therapeutic target. The biological role of ZP3 in cancer growth and progression is still unknown. We found that ~88% of the analyzed adenocarcinoma, squamous and small cell lung carcinomas to express ZP3. Knockout of ZP3 in a ZP3‐expressing lung adenocarcinoma cell line, significantly decreased cell viability, proliferation, and migration rates in vitro. Zona pellucida 3 knock out (ZP3‐KO) cell tumors inoculated in vivo in immunodeficient non‐obese diabetic, severe combined immunodeficient mice showed significant inhibition of tumor growth and mitigation of the malignant phenotype. RNA sequencing revealed the deregulation of cell migration/adhesion signaling pathways in ZP3‐KO cells. This novel functional relevance of ZP3 in lung cancer emphasized the suitability of ZP3 as a target in cancer immunotherapy and as a potential cancer biomarker.